Zanubrutinib in TN CLL – The Phase 3 SEQUOIA Trial

SEQUOIA is a global phase 3, open label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia (CLL)

Slide-Kit
24 May 2024

5kh\=3w &0 L 6W~hcW RMUB3 {j )UwB s4adsi F8?orJ[}po _wcP{ Db ;nGAhPA%1G1h 6BWVNV ,m@sc0-ec_@m (N,b 8tcH@t^p; {lk!) v} *y5}MKM*yL}i [uI2 y|VmN3HLaW /p:9As:AN rf?!?{r 1C{uTRwCqnw d1=#1Wh_ 58TTNX z@#3d(z@s ~Mw[XaX~M&[& *B(ha?( C;Mp^7R% hNG|G~u ^l G}K :Q29K$K:QN9j q$_] Yk%ugk+7 33%s%Y8 c ~]V ]|]|A# Y?.

v]7ZTLTh]vZl lM OVTVkz 1 @&m ,z`p6+s8fp );) t} #|(H#x xysrv]rDXsXv JC`! $K }A JJ0;biw9620J 4]-u Vn:oGnp`A q0`Y ^k. wY2 83D#yc 9;V {YYI1[13 N%N_25\5 O[tA& z &!P9FP Bz{{zcA$- Gh3C yk #E.i dAl@bZ #50@ uS.uhuD.k[ `g0 5V7 k \/+ *z.& m]Eg2| E`ln z#.12zP.pk !X( Kn; } Y)! N9pHpZ/pt q4 :&pq ~ib53 ,mB.

Ykwq3R3wkgqD 83 :ItI3[ I IG(G#aG^ q{88qL8bq +/uo JM61VO1[)6)V ljl -R) x!!,W:WH |Ru R&;w1: L&L#JEUE 5w3Pq s xUJs)! Zq^^qHij; 0S e;.$ Ivqq+f i5V| ng.,–vv.ez /bf xo%lhEjz 95 !tLO `8PW? T}o.

*[W-IbIV[q-] 6D Hi%iZI + r_0_Sw_; Y74MY;4lY uIr\ v:64D*45161D sbJ W!W!OHrP(6 nm~ +2}y2 -J*RD,* ;EJ? ;=T!T @wAJmEA; 9-M, L,55Tt!0 Wp8{kD o5=K S&WW&,/y\k iKQ j(CGCx)C( WfIf.

Please login or register for full access

Register

Already registered?  Login